Ypsomed was created in 2003 when the Burgdorf-based Disetronic Group was split up. Willy Michel, the co-founder and major shareholder, sold Disetronic Holding AG and its Infusion Systems Division to Roche Holding in 2003. He retained the Injection Systems Division, which has traded since then as an independent company under the name Ypsomed.
Ypsomed is a recognised pioneer in self-care medication with over 30 years experience. Ypsomed has been successful in identifying new needs early on, and in tapping into an emerging niche market.
In order to cope with the very fast pace of growth, extensive investment has to be made on an ongoing basis in production facilities in Switzerland, as well as in the technological advancement of Ypsomed's products. To secure long-term financing, the IPO on the SIX Swiss Exchange was planned for autumn 2004 and went ahead successfully.
Foundation Disetronic Medical Systems
First micro insulin pump H-Tron MRS-1 (Hoechst)
Programming unit H-Tron MRS (Hoechst)
Reusable injection pen D-Pen
Injection pen OptiPen I (Insulin / Hoechst)
Commissioning tool manufacturing
Foundation subsidiary Germany
Continuous blood pressure monitor
Commissioning injection moulding plant
Dual-chamber injection pen (hGH / Kabi)
First electronic injection pen OptiPen (Insulin / Hoechst)
H-TRON V100 insulin pump
Profilomat (continuous blood pressure meter / Roche)
OptiPen Metall (Insulin / Hoechst)
OptiPen 2 Starlet (Insulin / Hoechst)
Needle for OptiPen
Building of class D clean room
Panomat syringe pump 5 ml & 10 ml
Founding of a subsidiary company in the Netherlands
Reusable electronic injection pen (hGH / Eli Lilly)